{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:16:26Z","timestamp":1791317786221,"version":"4.3.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.autrev.2021.102756","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T03:10:31Z","timestamp":1610939431000},"page":"102756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pathophysiologic role of Interleukin-33\/ST2 in Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"20","author":[{"given":"Muhammad S.","family":"Soyfoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Nicaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.autrev.2021.102756_bb0005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2021.102756_bb0010","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10067-018-4153-8","article-title":"Advances in the diagnosis and treatment of Sjogren\u2019s syndrome","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/03009742.2010.536164","article-title":"The point prevalence of clinically relevant primary Sjogren\u2019s syndrome in two Norwegian counties","volume":"40","author":"Goransson","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102756_bb0020","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sjogren\u2019s syndrome: a systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.autrev.2018.06.015","article-title":"Arthritis in primary Sj\u00f6gren\u2019s syndrome: characteristics, outcome and treatment from French multicenter retrospective study","volume":"18","author":"Mirouse","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2018.09.003","article-title":"Novel autoantibodies in Sj\u00f6gren\u2019s syndrome: a comprehensive review","volume":"18","author":"Mart\u00edn-Nares","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2021.102756_bb0045","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jcp.21.5.656","article-title":"Labial salivary gland biopsy in Sjogren\u2019s disease","volume":"21","author":"Chisholm","year":"1968","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102756_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102690","article-title":"Minor salivary gland biopsy: its role in the classification and prognosis of Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Bautista-Vargas","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.rdc.2008.08.006","article-title":"Mucosa-associated lymphoid tissue lymphoma in Sjogren\u2019s syndrome: risks, management, and prognosis","volume":"34","author":"Voulgarelis","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2021.102756_bb0065","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.autrev.2019.03.003","article-title":"Free light chains and autoimmunity","volume":"18","author":"Napodano","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102756_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0075","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.rdc.2008.08.004","article-title":"New concepts in the pathogenesis of Sjogren\u2019s syndrome","volume":"34","author":"Delaleu","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0714.2008.00700.x","article-title":"Activation of innate immune responses through toll-like receptor 3 causes a rapid loss of salivary gland function","volume":"38","author":"Deshmukh","year":"2009","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102756_bb0085","first-page":"1019","article-title":"Toll-like receptor in salivary glands from patients with Sjogren\u2019s syndrome: functional analysis by human salivary gland cell line","volume":"34","author":"Kawakami","year":"2007","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2249.2006.03311.x","article-title":"Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren\u2019s syndrome","volume":"147","author":"Spachidou","year":"2007","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0095","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.tripleo.2010.01.006","article-title":"Expression of toll-like receptors 7, 8, and 9 in primary Sjogren\u2019s syndrome","volume":"109","author":"Zheng","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0100","first-page":"14","article-title":"One year in review 2018: Sjogren\u2019s syndrome","volume":"112","author":"Argyropoulou","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/art.27318","article-title":"Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjogren\u2019s syndrome correlates with increased inflammation","volume":"62","author":"Bikker","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1573397112666160714164149","article-title":"Update on pathogenesis of Sjogren\u2019s syndrome","volume":"13","author":"Sandhya","year":"2017","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.autrev.2021.102756_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaut.2017.11.003","article-title":"Th17 cells in primary Sjogren\u2019s syndrome: pathogenicity and plasticity","volume":"87","author":"Verstappen","year":"2018","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","article-title":"Activation of the type I interferon pathway in primary Sjogren\u2019s syndrome","volume":"35","author":"Mavragani","year":"2010","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sjogren\u2019s syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"issue":"9","key":"10.1016\/j.autrev.2021.102756_bb0130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sjogren\u2019s syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"18","key":"10.1016\/j.autrev.2021.102756_bb0135","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2174\/1381612821666150316120024","article-title":"Mouse models of primary Sjogren\u2019s syndrome","volume":"21","author":"Park","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2021.102756_bb0140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clim.2017.05.001","article-title":"What can Sjogren\u2019s syndrome-like disease in mice contribute to human Sjogren\u2019s syndrome?","volume":"182","author":"Peck","year":"2017","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0145","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1601-0825.2007.01376.x","article-title":"Usefulness of mouse models to study the pathogenesis of Sjogren\u2019s syndrome","volume":"13","author":"Soyfoo","year":"2007","journal-title":"Oral Dis"},{"issue":"12","key":"10.1016\/j.autrev.2021.102756_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102686","article-title":"The NZB\/W F1 mouse model for Sj\u00f6gren\u2019s syndrome: a historical perspective and lessons learned","volume":"19","author":"Bagavant","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaut.2010.06.011","article-title":"The role of intrinsic epithelial activation in the pathogenesis of Sjogren\u2019s syndrome","volume":"35","author":"Manoussakis","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102756_bb0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","article-title":"Mechanisms and new strategies for primary Sjogren\u2019s syndrome","volume":"68","author":"Mavragani","year":"2017","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0165","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2249.2002.01752.x","article-title":"CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren\u2019s syndrome patients indicating their intrinsic activation","volume":"127","author":"Dimitriou","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaut.2010.06.006","article-title":"Salivary gland epithelial cells (SGEC): carriers of exquisite B7-2 (CD86) costimulatory molecules","volume":"35","author":"Kapsogeorgou","year":"2010","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2021.102756_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1191\/0961203306lu2290rr","article-title":"The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren\u2019s syndrome (autoimmune epithelitis)","volume":"15","author":"Mitsias","year":"2006","journal-title":"Lupus."},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.autrev.2021.102756_bb0185","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sjogren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102756_bb0190","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/1744666X.2018.1519396","article-title":"Interferon activation in primary Sjogren\u2019s syndrome: recent insights and future perspective as novel treatment target","volume":"14","author":"Bodewes","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0195","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","article-title":"B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren\u2019s syndrome","volume":"8","author":"Ittah","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2021.102756_bb0200","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/eji.200738008","article-title":"Systemic increase in type I interferon activity in Sjogren\u2019s syndrome: a putative role for plasmacytoid dendritic cells","volume":"38","author":"Wildenberg","year":"2008","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102756_bb0205","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","article-title":"Pathogenetic mechanisms in the initiation and perpetuation of Sjogren\u2019s syndrome","volume":"6","author":"Voulgarelis","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2021.102756_bb0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2017.03.007","article-title":"Insight into pathogenesis of Sjogren\u2019s syndrome: dissection on autoimmune infiltrates and epithelial cells","volume":"182","author":"Goules","year":"2017","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1601-0825.2006.01292.x","article-title":"Sjogren\u2019s syndrome: why autoimmune epithelitis?","volume":"12","author":"Mitsias","year":"2006","journal-title":"Oral Dis"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0220","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.berh.2007.09.001","article-title":"Update on Sjogren\u2019s syndrome autoimmune epithelitis: from classification to increased neoplasias","volume":"21","author":"Tzioufas","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0225","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity."},{"issue":"11","key":"10.1016\/j.autrev.2021.102756_bb0230","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102756_bb0235","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.autrev.2021.102756_bb0240","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1084\/jem.20130351","article-title":"A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis","volume":"210","author":"Salimi","year":"2013","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ni.3370","article-title":"Interleukin 33 is a guardian of barriers and a local alarmin","volume":"17","author":"Martin","year":"2016","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","article-title":"Barrier epithelial cells and the control of type 2 immunity","volume":"43","author":"Hammad","year":"2015","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","article-title":"Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases","volume":"31","author":"Luthi","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2021.102756_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2014.09.004","article-title":"IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy","volume":"31","author":"Cayrol","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102756_bb0265","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.4049\/jimmunol.0802729","article-title":"The essential role of single Ig IL-1 receptor-related molecule\/Toll IL-1R8 in regulation of Th2 immune response","volume":"182","author":"Bulek","year":"2009","journal-title":"J Immunol"},{"issue":"37","key":"10.1016\/j.autrev.2021.102756_bb0270","doi-asserted-by":"crossref","first-page":"14918","DOI":"10.1073\/pnas.1308651110","article-title":"Structural insights into the interaction of IL-33 with its receptors","volume":"110","author":"Liu","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"10.1016\/j.autrev.2021.102756_bb0275","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0280","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky","year":"2015","journal-title":"Immunity."},{"issue":"10","key":"10.1016\/j.autrev.2021.102756_bb0285","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1002\/eji.200737547","article-title":"IL-33 is a chemoattractant for human Th2 cells","volume":"37","author":"Komai-Koma","year":"2007","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrrheum.2011.53","article-title":"Interleukin-33 biology with potential insights into human diseases","volume":"7","author":"Palmer","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102756_bb0295","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2008-05-157818","article-title":"Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33","volume":"113","author":"Pecaric-Petkovic","year":"2009","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.autrev.2021.102756_bb0300","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102756_bb0305","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1073\/pnas.1201042109","article-title":"Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice","volume":"109","author":"Yasuda","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.autrev.2021.102756_bb0310","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.autrev.2021.102756_bb0315","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1002\/eji.201444671","article-title":"IL-33 attenuates the development of experimental autoimmune uveitis","volume":"44","author":"Barbour","year":"2014","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102756_bb0320","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1136\/ard.2010.148247","article-title":"Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement","volume":"70","author":"Manetti","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0325","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis","volume":"205","author":"Miller","year":"2008","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0330","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","article-title":"Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus","volume":"49","author":"Mok","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2021.102756_bb0335","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.4049\/jimmunol.0802387","article-title":"Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells","volume":"183","author":"Prefontaine","year":"2009","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102756_bb0340","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1136\/gutjnl-2011-301785","article-title":"Neutralisation of the interleukin-33\/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice","volume":"62","author":"Sedhom","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.autrev.2021.102756_bb0345","doi-asserted-by":"crossref","first-page":"985301","DOI":"10.1155\/2013\/985301","article-title":"Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis","volume":"2013","author":"Tang","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0350","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0355","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.173.1.145","article-title":"A novel therapy of murine collagen-induced arthritis with soluble T1\/ST2","volume":"173","author":"Leung","year":"2004","journal-title":"J Immunol"},{"issue":"31","key":"10.1016\/j.autrev.2021.102756_bb0360","doi-asserted-by":"crossref","first-page":"10913","DOI":"10.1073\/pnas.0801898105","article-title":"IL-33 exacerbates antigen-induced arthritis by activating mast cells","volume":"105","author":"Xu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0365","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.4049\/jimmunol.1002103","article-title":"IL-33 activates B1 cells and exacerbates contact sensitivity","volume":"186","author":"Komai-Koma","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102756_bb0370","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/art.24305","article-title":"Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis","volume":"60","author":"Palmer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0375","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-203187","article-title":"Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren\u2019s syndrome","volume":"73","author":"Awada","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102756_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/srep42413","article-title":"Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease","volume":"7","author":"Furukawa","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0385","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3899\/jrheum.140234","article-title":"The interleukin 33\/ST2 axis in patients with primary Sjogren syndrome: expression in serum and salivary glands, and the clinical association","volume":"42","author":"Jung","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0390","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijo.IJO_405_17","article-title":"Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease","volume":"66","author":"Luo","year":"2018","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102756_bb0395","first-page":"1295","article-title":"The IL33\/ST2 axis in Sjogren syndrome in relation to disease activity","volume":"20","author":"Margiotta","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cyto.2013.07.006","article-title":"Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren\u2019s syndrome","volume":"64","author":"Zhao","year":"2013","journal-title":"Cytokine."},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0405","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.rdc.2017.06.007","article-title":"Neuromyelitis optica","volume":"43","author":"Patterson","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0410","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/cns.12774","article-title":"Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders","volume":"24","author":"Zhang","year":"2018","journal-title":"CNS Neurosci Ther"},{"issue":"9976","key":"10.1016\/j.autrev.2021.102756_bb0415","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.autrev.2021.102756_bb0420","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10735-018-9796-x","article-title":"Mechanism of fibrogenesis in submandibular glands in patients with IgG4-RD","volume":"49","author":"Yajima","year":"2018","journal-title":"J Mol Histol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: all we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0430","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/03009742.2011.633099","article-title":"Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren\u2019s syndrome","volume":"41","author":"Dupire","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0435","first-page":"129","article-title":"Phagocyte-specific S100A8\/A9 is upregulated in primary Sjogren\u2019s syndrome and triggers the secretion of pro-inflammatory cytokines in vitro","volume":"35","author":"Nicaise","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0440","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/ard.2011.154013","article-title":"Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren\u2019s syndrome","volume":"71","author":"Ciccia","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102756_bb0445","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/eji.201040647","article-title":"A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation","volume":"41","author":"Bourgeois","year":"2011","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102756_bb0450","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/eji.200838575","article-title":"The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production","volume":"39","author":"Bourgeois","year":"2009","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102756_bb0455","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.diabet.2017.06.008","article-title":"IL-33 receptor ST2 deficiency attenuates renal ischaemia-reperfusion injury in euglycaemic, but not streptozotocin-induced hyperglycaemic mice","volume":"44","author":"Sehnine","year":"2018","journal-title":"Diabetes Metab"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722100015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722100015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:52Z","timestamp":1761600052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722100015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S156899722100015X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102756","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiologic role of Interleukin-33\/ST2 in Sj\u00f6gren's syndrome","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102756"}}